Trial Profile
A Phase 2 Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Sotigalimab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Apexigen
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 19 Jan 2023 According to an Apexigen media release, results from this trial will be presented at the ASCO Gastrointestinal Cancers Symposium 2023.
- 13 Sep 2022 Results assessing safety and efficacy of combining sotiga with neoadjuvant chemoradiation in patients with esophageal/gastroesophageal junction cancers, presented at the 47th European Society for Medical Oncology Congress.